Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated June 17, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 66,000 people across 80 countries. The filing details transactions executed under a specific sub-programme initiated on May 6, 2024, and provides an aggregate update on the broader 12-month repurchase plan.
Key Financial Metrics and Share Repurchase Activity
The filing focuses exclusively on capital allocation via share buybacks rather than operational financial performance metrics such as revenue or profit.
- Total Repurchase Programme: Up to DKK 20 billion over a 12-month period beginning February 6, 2024.
- Specific Sub-Programme (May 6 – August 5, 2024): Up to DKK 2.2 billion.
- Accumulated Repurchases (as of June 14, 2024): 9,703,295 B shares purchased since February 6, 2024.
- Total Transaction Value (since Feb 6): DKK 8,432,046,688.
- Average Purchase Price (since Feb 6): DKK 868.99 per B share.
- Treasury Shares Held: 11,068,859 B shares (0.2% of total share capital).
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Transaction Details
Between June 10 and June 14, 2024, the company executed daily repurchases under the May 6 sub-programme. The average purchase price during this specific window ranged from DKK 985.97 to DKK 987.46, which is higher than the overall average price of DKK 868.99 since the start of the full programme in February.
| Date | Number of B Shares | Average Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| June 10, 2024 | 37,500 | 985.97 | 36,973,830 |
| June 11, 2024 | 37,000 | 986.49 | 36,500,308 |
| June 12, 2024 | 36,000 | 987.46 | 35,548,672 |
| June 13, 2024 | 36,000 | 987.32 | 35,543,448 |
| June 14, 2024 | 36,000 | 986.41 | 35,510,821 |
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 20 billion limit during the 12-month period starting February 6, 2024. As of June 14, approximately DKK 8.43 billion of this total has been utilized.
Risks and Contingencies: The filing does not disclose specific operational risks, contingencies, or unusual items. It notes that the programme is executed in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Key Facts for Investor Verification
- Remaining Capacity: Verify the remaining amount available for repurchase under the DKK 20 billion programme (approximately DKK 11.57 billion as of June 14).
- Share Price Trend: Note the increase in average purchase price in June (approx. DKK 986) compared to the programme average (DKK 869), indicating a rising stock price during the reporting period.
- Treasury Impact: Confirm that treasury shares currently represent only 0.2% of the total share capital.
- Operational Data: Acknowledge that this filing contains no operational financial results; investors must refer to the company's most recent Form 20-F or quarterly reports for revenue and earnings data.